MRK vs ONMD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating the weakest possible financial health. With a negative Price-to-Book ratio of -15.47 and a Current Ratio of 0.43, ONMD is facing a severe liquidity crisis and possesses negative shareholder equity. While the reported revenue growth of 3326.90% is astronomical, it is offset by a negative gross margin (-37.01%) and massive operating losses, suggesting that growth is currently being achieved at an unsustainable cost. The combination of bearish insider activity and a total lack of profitability makes this a high-risk speculative asset.
Compare Another Pair
Related Comparisons
MRK vs ONMD: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and OneMedNet Corporation (ONMD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.